New hope for leukemia patients: Chemo-Free approach shows promise
NCT ID NCT04747912
First seen Apr 01, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study tests adding a targeted drug called inotuzumab ozogamicin (InO) to standard treatment for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this combination can make the cancer disappear faster and more completely. About 25 participants will receive the drug combo, and researchers will check for remission at 60 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60615, United States
Conditions
Explore the condition pages connected to this study.